Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Invested Capital: 2022-2025

Historic Invested Capital for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $193.7 million.

  • Axsome Therapeutics' Invested Capital fell 29.01% to $193.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $193.7 million, marking a year-over-year decrease of 29.01%. This contributed to the annual value of $237.0 million for FY2024, which is 36.11% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Invested Capital is $193.7 million, which was up 0.34% from $193.1 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Invested Capital peaked at $458.8 million during Q2 2023, and registered a low of $64.7 million during Q1 2022.
  • For the 3-year period, Axsome Therapeutics' Invested Capital averaged around $298.0 million, with its median value being $272.9 million (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 316.34% in 2023, then slumped by 39.29% in 2024.
  • Axsome Therapeutics' Invested Capital (Quarterly) stood at $204.6 million in 2022, then spiked by 81.36% to $371.0 million in 2023, then slumped by 36.11% to $237.0 million in 2024, then fell by 29.01% to $193.7 million in 2025.
  • Its last three reported values are $193.7 million in Q3 2025, $193.1 million for Q2 2025, and $233.2 million during Q1 2025.